key: cord-0701863-56bo9s2m
authors: Abbas, Hassan M.; Al‐Jumaili, Ali Azeez; Nassir, Kawthar F.; Al‐Obaidy, Muhammed Waheeb; Al Jubouri, Adnan Mohammed; Dakhil, Basim Dhawi; Abdulelah, Mohammed Mahir; Al Khames, Qutaiba Ahmed
title: Assessment of COVID‐19 Treatment containing both Hydroxychloroquine and Azithromycin: A natural clinical trial
date: 2020-12-05
journal: Int J Clin Pract
DOI: 10.1111/ijcp.13856
sha: ffc20ebd2ea32fe5b8afc325265fdd452b835da0
doc_id: 701863
cord_uid: 56bo9s2m

The goal of this study was to assess the clinical effectiveness and safety profile of the COVID‐19 treatment protocol (containing both hydroxychloroquine (HCQ) and azithromycin) in an Iraqi specialised hospital. METHODS: This prospective study used a pre‐ and post‐intervention design without a comparison group. The intervention was routine Ministry of Health (MOH) approved the management of COVID‐19 for all patients. The study was conducted in a public healthcare setting in Baghdad, Iraq from March 1st to May 25, 2020. The study outcome measures included the changes in clinical and biochemical parameters during the hospitalisation period. Paired t‐test and Chi‐square test were used to compare the measures of vital signs, lab tests and symptoms before and after treatment. RESULTS: The study included 161 patients who were admitted with positive RT‐PCR and clinical symptoms of COVID‐19. In terms of severity, 53 (32.9%) patients had amild condition, 47 (29.2%) had moderate condition, 35 (21.7%) had severe condition and 26 (16.1%) had critical condition. Most patients (84.5%) recovered and were discharged without symptoms after testing negative with RT‐PCR, while 11 (6.8%) patients died during the study period. The signs and symptoms of COVID‐19 were reduced significantly in response to a therapy regimen containing HCQ and azithromycin. The most common reported side effects were stomach pain, hypoglycemia, dizziness, itching, skin rash, QT prolongation, arrhythmia, and conjunctivitis. CONCLUSIONS: This natural trial showed that the COVID‐19 regimen containing both HCQ and azithromycin can be helpful to promote the recovery of most patients and reduced their signs and symptoms significantly. It also shows some manageable side effects mostly those related to heart rhythm. In the absence of FDA‐approved medications to treat COVID‐19, the repurposing of HCQ and azithromycin to control the disease signs and symptoms can be useful.

caused by a newly emergent coronavirus that was first recognised in Wuhan, China, in December 2019. 1 Genetic sequencing of the virus suggests that it is a beta-corona virus closely linked to the SARS virus. 2 While most people with COVID-19 develop the only mild or uncomplicated illness, approximately 14% develop a severe disease that requires hospitalisation and oxygen support, and 5% require admission to an intensive care unit. 3 In severe cases, COVID-19 can be complicated by acute respiratory distress syndrome (ARDS), sepsis and septic shock, multiorgan failure, including acute kidney injury and cardiac injury. 3 Older age and co-existing diseases have been reported as risk factors for death. 4 On March 12, the WHO officially declared the COVID-19 outbreak a pandemic. 5 As of June 24, 2020, COVID-19 was confirmed in 188 countries with a total confirmed cases of 9,295,365 and more than 478,289 deaths. 6 Iraq had 36,702 confirmed cases, 16,814 recovered cases and 1,330 deaths associated with COVID-19 pandemic as of June 24, 2020. 6 The pandemic of COVID-19 is caused by the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and presents a challenge in regard to identifying effective drugs for prevention and treatment. Up to the time of writing this manuscript, there were no medications approved by the US Food and Drug Administration (FDA) to treat COVID-19. 7 However, the FDA recently created a new emergency programme, the Coronavirus Treatment Acceleration Programme (CTAP), aimed at speeding up research for the development of COVID-19 treatments. 8, 9 As of May 11, 2020, more than 144 clinical trials had been launched to test COVID-19 treatments, including some drug repurposing or repositioning. 8, 9 Researchers are also testing medications typically used to treat other conditions to see if they are also effective in treating COVID-19. For example, hydroxychloroquine (HCQ) and chloroquine are two medications that have been used for many decades to treat malaria and autoimmune conditions such as rheumatoid arthritis and lupus, 10 and azithromycin is an antibiotic commonly used to treat bacterial infections such as bronchitis and pneumonia. They have been shown to have some in vitro activity against viruses such as influenza A and Zika. 11 We are ethically committed to share the experience of Iraqi healthcare providers with COVID-19 treatment with the scientific community to help answer some questions about the effectiveness and safety of HCQ and azithromycin containing regimen. The Iraqi Scientific Committee at the Ministry of Health (MOH) adopted a treatment protocol on March 1st, 2020 several days after the detection of the first COVID-19 case in Iraq on February 24, 2020 ( Table 1) . 12 The goal of this study was to assess the clinical effectiveness and safety profile of the current COVID-19 treatment protocol (containing both HCQ and azithromycin) in an Iraqi specialised hospital.

This prospective study used a pre-and post-intervention design. Exclusion criteria included known allergy to hydroxychloroquine (HCQ) or chloroquine, any contraindications to HCQ or chloroquine and azithromycin including retinopathy and prolonged QT, patients with severely reduced in left ventricular (LV) function, severely reduced in renal function and G6PD deficiency in addition to pregnant and lactating women.

The research team (clinical pharmacist and three specialist physicians) was part of the medical team in the centre. They prospectively collected patient medical information from patients, patient records and attending physicians. The information included demographics, disease and treatment characteristics and clinical outcome. Patient's clinical conditions and routine biochemical tests were assessed at baseline and then every day to evaluate the effect of therapy protocol.

The study outcome measures were assessed at baseline (at admission) and daily after hospitalisation (post-intervention) until the discharge of the recovered patient or death. The study outcome measures included the changes in clinical and biochemical parameters during hospitalisation period such as the disappearance of clinical symptoms,

There is a controversy about using hydroxychloroquine and azithromycin to treat COVID-19 because of uncertainly about their effectiveness and safety.

• The experience with Iraqi protocol to treat COVID-19

can help to answer some questions about the effectiveness and safety of this therapy combination which can offer some support to the international community in facing such a vicious pandemic.

• This natural trial showed that the COVID-19 regimen containing both HCQ and azithromycin can be helpful to promote the recovery of most patients and reduced their signs and symptoms significantly.

The trial was not registered because it is a natural trial (quasi-experiment) which was conducted according to the Iraqi Ministry of Health protocol by a regular healthcare team who is planning to share its experience with the international scientific community.

virologic clearance and occurrence of side effects. The routine assessment of vital signs was conducted three times daily. Virologic clearance was measured using real-time PCR which was retested at day 6 post hospitalisation. Complete recovery was defined as two negative RT-PCR tests (which were usually performed on days 6th and 7th of hospitalisation). Fourteen days after hospital discharge, recovered patients were retested in outpatient clinics using RT-PCR.

Other outcome measures included the time to clinical recovery (TTCR) and final clinical prognosis (recovery vs death). The TTCR is defined as the time to the disappearance of clinical symptoms (eg, cough and shortness of breath, SOB) and a normal body temperature and respiratory rate for more than 72 hours.

Study participants with confirmed cases of COVID-19 were transferred to the study specialised centre after having a positive RT-PCR test at one of the Medical City Hospitals. After admission, COVID-19 patients were classified according to clinical evaluation to mild cases (no pneumonia on a CT scan), moderate cases (pneumonia on a CT scan), severe cases (respiratory rate ≥ 30 breaths /min, oxygen saturation ≤ 93% or patients with pneumonia on a CT scan) and critical cases (respiratory failure/need mechanical ventilation). All patients were treated according to the MOH treatment protocol which relies on patient severity status (Table 1) .

To assess radiological changes, a chest CT scan was conducted before starting the treatment (day 0) and after 5 days of treatment (day 6). Pulmonary status was classified into three levels:

Exacerbated, unchanged, and improved. Medication safety was also assessed by monitoring adverse drug reactions (ADRs), vital signs and lab tests. Routine lab tests during the treatment period included liver function tests, renal function tests and fasting blood sugar. Liver function tests included alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and total bilirubin. Renal function was assessed using serum urea and F I G U R E 1 The effect of treatment on patient clinical condition (signs and symptoms). Before therapy was measured at baseline (at admission). Vital sign measurements after therapy equal the average of the last three-day measurements. Frequency of patients with symptoms (cough/SOB) after therapy was measured on the last day before discharge. SOB, shortness of breath, RR, respiratory rate, SBP, systolic blood pressure, DBP, diastolic blood pressure, PR, pulse rate

The effect of treatment on FBS, WBCs, and Hg levels. FBS, fasting blood sugar; WBCs, white blood cells; Hg, hemoglobin creatinine (s.cr). The WHO-UPPSALA causality assessment criteria were used to determine the causality of adverse drug reactions (ADRs) of hydroxychloroquine and azithromycin. 13 All data were recorded in the patient medical record. Consent was obtained from the patients before giving the therapy regimen.

The researchers de-identified patient names and addresses to keep patient confidentiality. The study was approved by the Higher Ethical Committee at Medical City Hospitals.

Statistical Package for the Social Sciences 22 (SPSS, Chicago, IL, USA) was used to analyse the data. For descriptive analysis, categorical variables were presented as frequencies and percentages, while continuous variables were described using mean and standard deviation. A paired t-test was used to compare the means of vital signs and lab tests before and after treatment. The Chi-square test was used to compare categorical variables (presence of fever and cough) before and after treatment. A P-value < .05 was considered to be statistically significant. (Table 5 ). In other words, those signs and symptoms of COVID-19 patients were reduced significantly after using a therapy regimen containing HCQ and azithromycin. However, there were non-significant effects of treatment (P-value ≥ .05) on systolic blood pressure (SBP), diastolic blood pressure (DBP), AST, ALT, ALP, total bilirubin, serum urea, and serum creatinine (Figures 1 and 2) .

In terms of adverse drug reactions (ADRs), the most commonly reported ones were stomach pain/cramps, hypoglycemia, headaches, mood changes, dizziness, itching, diarrhoea, muscle weakness, nausea, skin rash, vomiting, QT prolongation, arrhythmia, and conjunctivitis ( Figure 3) . Most ADRs were possible to be caused by HCQ and/or azithromycin. It means they also can be caused by the disease (COVID-19) . Moreover, three ADRs including arrhythmia, QT prolongation and conjunctivitis were probably caused by the two medications (Table 6 ). In other words, they unlikely to be attributed to COVID-19 disease. The electrocardiograph (ECG) of six (3.7%) patients recorded QTc prolongation, but not more than 450ms. Additionally, arrhythmia was reported in three (1.9%) other patients ( Table 6 ). The medical team stopped the HCQ and azithromycin treatment for three patients who experienced arrhythmia.

Then electrolyte levels (calcium and potassium) were measured and corrected to treat the arrhythmia. However, this treatment stoppage occurred after completing the first five days of the therapy course. During the study period, the use of convalescent plasma to treat COVID-19 had not been started in the study setting.

In this study, the treatment regimen (containing both HCQ and azithromycin) appeared to help promote recovery in 150 COVID-19 patients (83.2%) in the study centre. Although 16% of patients were admitted in critical condition and 26% were admitted to the RCU, the mortality rate was only 6.8%. It is worth mentioning that most The study found a significant reduction of the viral carriage in the HCQ/azithromycin group compared with the control group at day 6 post-inclusion. The study reported 100% viral clearance in nasopharyngeal swabs with the combination of HCQ and azithromycin compared with 57.1% in HCQ alone group and 12.5% in patients who did not receive HCQ (P < .001). 17 Chloroquine and HCQ appear to block viral entry into cells by inhibiting the glycosylation of host receptors, proteolytic processing, and endosomal acidification. 18, 19 These agents also have immunomodulatory effects through the attenuation of cytokine production and inhibition of autophagy and lysosomal activities in host cells. 19, 20 HCQ has in-vitro activity against SARS-CoV-2 with half-maximal effective concentration (EC50) of 6.14 μM which is lower than that of chloroquine (EC50 = 23.90 μM) after 24 hours of growth. 18 Moreover, some manageable side effects of HCQ were reported during the treatment period. These side effects may disappear during treatment as the body adjusts to the medicine. 21 The reported side effects included stomach pain/cramps, hypoglycemia, headaches, mood changes, dizziness, itching, diarrhoea, muscle weakness, nausea, skin rash, and vomiting. Those are common HCQ side effects and appear to be dose-dependent and most often occur with loading doses of 800 mg or higher. 22 In this study, we used an HCQ maintenance dose of 400 mg daily for a short-term course which is relatively safe since the recommended daily dose was not exceeded. The most severe and life-threatening complications from the use of hydroxychloroquine include QT interval prolongation and the resultant risk of ventricular arrhythmias. 23 In our study, the electrocardiogram (ECG) monitoring showed that six patients developed QT interval prolongation, but not more than 450ms which did not require medical intervention. In contrast, three patients developed arrhythmia and needed medical intervention which consisted of stopping the treatment and normalising the blood electrolytes (potassium and calcium). The incidence of QT interval prolongation with using chloroquine and hydroxychloroquine is highly dependent on baseline ECG findings, with risk exacerbated using concomitant QT-interval prolonging medications. 24 The combination of azithromycin with HCQ frequently prolongs the QT interval in a clinically significant This study had some limitations. It was conducted in a single-centre without a comparison group. Single-centre findings may not be generalisable. However, a universal therapy regimen has been implemented by the health top authority across all country healthcare settings. Lack of a comparison group can limit the determination of causality between the therapy and the cure or good prognosis.

Additionally, some disease-induced symptoms overlap with ADRs during treatment period.

This natural trial showed that the COVID-19 regimen containing both HCQ and azithromycin is helpful in treating the majority of patients and reduced their signs and symptoms significantly. It also causes some manageable side effects mostly those related to heart rhythm.

In the absence of FDA-approved medications to treat COVID-19, the repurposing of HCQ and azithromycin to control the disease signs and symptoms is potentially useful. The study showed that using this therapy combination (HCQ and azithromycin) is promising and can fill the gap until more effective treatments are found. Future randomised controlled trial can give more definite answers about the effectiveness and safety of such therapy protocol.

The authors would like to thank Dr Jawad Rasheed, Dr Ali AL-Garrawy and all the physicians and healthcare provider in Al-Shifaa

Centre for Corona pandemic at Medical City, Baghdad who helped the research team conduct the study. If they had not bravely risked their lives to treat the COVID-19 cases, there would not be such a high recovery rate amongst patients.

No conflict of interest to declare and the study received no fund.

Hassan M Abbas, BS Pharm, MS, PhD, Participated in study con- 

Ali Azeez Al-Jumaili https://orcid.org/0000-0003-4691-0280

Kawthar F. Nassir https://orcid.org/0000-0002-4266-3115

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-A n update on the status

COVID-19: A novel zoonotic disease caused by a coronavirus from China: What we know and what we don't

Clinical management of patients with moderate to severe COVID-19 -Interim Guidance. Public Heal Agency Canada

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

WHO declares COVID-19 a pandemic

COVID-19 Dashboard

Diagnosis and Possible Therapeutic Options for COVID-19

Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19

Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review

Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID-19

The first 40-days experience and clinical outcomes in the management of coronavirus covid-19 crisis. Single center preliminary study

WHO Causality assessment

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges

Antimalarialsare they effective and safe in rheumatic diseases? Reumatologia

Can developing countries face novel coronavirus outbreak alone? The Iraqi situation

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Targeting endosomal acidification by chloroquine analogs as a promising strategy for the treatment of emerging viral diseases

Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A Review

Rethinking the role of hydroxychloroquine in the treatment of COVID-19

The side effect and the retention rate of hydroxychloroquine in Japan

Prevalence of hydroxychloroquine-induced side-effects in dermatology patients: A retrospective survey of 102 patients

Life threatening severe QTc prolongation in patient with systemic lupus erythematosus due to hydroxychloroquine

Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers

Experience with Hydroxychloroquine and Azithromycin in the COVID-19 Pandemic: Implications for QT Interval Monitoring. medRxiv

Chinese Centre for Disease Control and Prevention. COVID-19 Prevention and Control

Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

COVID-19 ) Update : FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine Inquiries